Lennon Search Associates Blog Celgene shells out $7.2B for Receptos in a big bet on autoimmune disease

Celgene is trading $7.2 billion in cash for Receptos and its Phase III autoimmune treatment, building on some recent success in the field. ...read more Source: Celgene shells out $7.2B for Receptos in a big bet on autoimmune disease